Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4

International Journal of Cancer

Volumn 71, Issue 4, 1997, Pages 660-667

  Gold, David V ^a   Cardillo, Thomas ^a   Vardi, Yehuda ^b   Blumenthal, Rosalynn ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY PAM4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031010328     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970516)71:4<660::AID-IJC24>3.0.CO;2-E     Document Type: Article

References (23)

1. ALISAUSKAS, R., WONG, G.Y.C. and GOLD, D.V., Initial studies of MAb-PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res. (Suppl.), 55, 5743s-5748s (1995).
2. BLUMENTHAL, R.D., KASHI, R., SHARKEY, R.M. and GOLDENBERG, D.M., Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int. J. Cancer, 61, 557-566 (1995).
3. 131I-labeled monoclonal antibodies. Cancer Res., 52, 6036-6044 (1992).
4. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int. J. Cancer, 41, 127-134 (1988).
5. DALTON, R.R., SARR, M.G., VANHEERDEN, J.A. and COLBY, T.V., Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery, 111, 489-494 (1992).
6. ESTEBAN, J.M., SCHLOM, J., MORNEX, F. and COLCHER, D., Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Europ. J. Cancer clin. Oncol., 23, 643-655 (1987).
7. GOLD, D.V., ALISAVSKAS, R. and SHARKEY, R.M., Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res., 55, 1105-1110 (1995).
8. GOLD, D.V., LEW, K., MALINIAK, R., HERNANDEZ, M. and CARDILLO, T., Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int. J. Cancer, 57, 204-210 (1994).
9. GOLDENBERG, D.M., Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. Amer. J. Gastroenterol., 86, 1392-1403 (1991).
10. GOLDROSEN, M.H., LOFTUS, R., LLOYD, F., BIDDLE, W., PAOLINI, N., HOLYOKE, E.D. and FOON, K.A., Localization of monoclonal antibody in a novel nude mouse model of pancreatic cancer. Proc. Amer. Assoc. Cancer Res., 29, 419 (1988).
11. JUWEID, M., SHARKEY, R.M., MARKOWITZ, A., BEHR, T.H., SWAYNE, L.C., HANSEN, H.J., SHEVITZ, J., LEUNG, S.-O., RUBIN, A.D., HERSKOVIC, T., HANLEY, D. and GOLDENBERG, D.M., Treatment of non-Hodgkin's lymphoma with radiolabeled murine. chimeric. or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. (Suppl.), 55, 5899-5907 (1995).
12. 131I-labeled monoclonal antibody Nd2 in xenografted nude mice. Jpn. J. Cancer Res., 87, 977-984 (1996).
13. KLAPDOR, R., MONTZ, R., GRETEN, H., CHATAL, J.F., DOUILLARD, J.Y., SACCAVINI, J.C. and DIETEL, M., Immunszintigraphie und Radioimmuntherapie des transpantierten Pankreaskarzinoms. Nucl. Med., 124, 227-231 (1985).
14. MANTEL, N. and HAENSZEL, W., Statistical aspects of the analysis of data from retrospective studies of disease. J. tun. Cancer Inst., 22, 719-748 (1959).
15. MARIANI, G., MOLEA, N., BACCIARDI, D., BOGGI, U., FORNACIARI, G., CAMPANI, D., SALVADORI, P.A., GIULIANOTTI, P.C., MOSCA, F., GOLD, D.V., SHARKEY, R.M. and GOLDENBERG, D.M., Initial tumor targeting, biodistribution and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res. (Suppl.), 55, 5511s-5515s (1995).
16. OKAMOTO, A., TSURUTA, K., ISAWA, T., KAMISAWA, K., TANAKA, Y. and ONODERA, T., Intraoperative radiation therapy for pancreatic carcinoma. Int. J. Pancreatol., 16, 157-164 (1994).
17. OTSUJI, E., YAMAGUCHI, R., YAMAOKA, N., KOTANI, T., KATO, M., TANIGUCHI, K., KIYAMURA, K. and TAKAHASHI, T., Biodistribution of murine and chimeric Fab fragments of the monoclonal antibody A7 in human pancreatic cancer. Pancreas. 10, 265-273 (1995).
18. 2 fragments of monoclonal antibodies to CA 19-9 and CEA. In: C. Winkler (ed.), Nuclear medicine in clinical oncology: current status and future aspects, pp. 391-396, Springer, New York (1986).
19. SHARKEY, R.M., GOLD, D.V., SWAYNE, L.C., CONTE, P. and GOLDENBERG, D.M., Initial clinical investigations of PAM4, a new murine monoclonal antibody against pancreatic cancer. Proc. nat. Acad. Sci. (Wash.), 35, 219 (1994).
20. SINDELAR, W.F., KINSELLA, T.J. and MAYER, R.J., Cancer of the pancreas. In: V.T. Devita, Jr., S. Hellman and S.A. Rosenherg (eds.), Cancer, principles and practice of oncology, pp. 691-739, Lippincott, Philadelphia (1985).
21. SMITH, F.P., HOTH, D.F., LEVINE, B., KERLIN, D.A., MACDONALD, J.S., WOOLLEY, P.V. and SCHEIN, P.S., 5-fluorouraeil. adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocurcinoma of the pancreas. Cancer, 46, 2014-2018 (1980).
22. WIGGANS, R.G., WOOLEY, P.V. and MACUONALD, J.S., Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer, 41, 387-391 (1978).
23. ZERBI, A., FOSSATI, V., PAROLINI, D., CARLUCCI, M., BALZANO, G., BODROGNA, G., STAUDACHHR, C. and DICARLO, V., Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer, 73, 2930-2935 (1994).